These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 19680291)

  • 1. The role of genetic testing in the prediction of response to EGFR inhibitors in NSCLC.
    Hirsch FR
    Oncogene; 2009 Aug; 28 Suppl 1():S1-3. PubMed ID: 19680291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors.
    John T; Liu G; Tsao MS
    Oncogene; 2009 Aug; 28 Suppl 1():S14-23. PubMed ID: 19680292
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shortcomings of current therapies for non-small-cell lung cancer: unmet medical needs.
    Burris HA
    Oncogene; 2009 Aug; 28 Suppl 1():S4-13. PubMed ID: 19680296
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of the molecular footprint of EGFR in tailoring treatment decisions in NSCLC.
    Gately K; O'Flaherty J; Cappuzzo F; Pirker R; Kerr K; O'Byrne K
    J Clin Pathol; 2012 Jan; 65(1):1-7. PubMed ID: 22039281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapies for non-small cell lung cancer.
    Dempke WC; Suto T; Reck M
    Lung Cancer; 2010 Mar; 67(3):257-74. PubMed ID: 19914732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary and secondary therapeutic strategies for EGF receptor pathway inhibition in non-small-cell lung cancer.
    Batus M; Fidler MJ; Bonomi PD
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1589-99. PubMed ID: 20942630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic treatment for advanced (stage IIIb/IV) non-small cell lung cancer: more treatment options; more things to consider. Introduction.
    Bunn PA; Thatcher N
    Oncologist; 2008; 13 Suppl 1():1-4. PubMed ID: 18263768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Searching for a magic bullet in NSCLC: the role of epidermal growth factor receptor mutations and tyrosine kinase inhibitors.
    Wong KK
    Lung Cancer; 2008 Jun; 60 Suppl 2():S10-8. PubMed ID: 18513579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting.
    Eberhard DA; Giaccone G; Johnson BE;
    J Clin Oncol; 2008 Feb; 26(6):983-94. PubMed ID: 18281673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic polymorphisms of the epidermal growth factor and related receptor in non-small cell lung cancer--a review of the literature.
    Araújo A; Ribeiro R; Azevedo I; Coelho A; Soares M; Sousa B; Pinto D; Lopes C; Medeiros R; Scagliotti GV
    Oncologist; 2007 Feb; 12(2):201-10. PubMed ID: 17296816
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly.
    Gridelli C; Massarelli E; Maione P; Rossi A; Herbst RS; Onn A; Ciardiello F
    Cancer; 2004 Oct; 101(8):1733-44. PubMed ID: 15386339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Individualized therapy in non-small-cell lung cancer: future versus current clinical practice.
    Pérez-Soler R
    Oncogene; 2009 Aug; 28 Suppl 1():S38-45. PubMed ID: 19680295
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier.
    Sangha R; Lara PN; Mack PC; Gandara DR
    Curr Opin Oncol; 2009 Mar; 21(2):116-23. PubMed ID: 19532012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epidermal growth factor receptor mutations in lung cancer.
    Sharma SV; Bell DW; Settleman J; Haber DA
    Nat Rev Cancer; 2007 Mar; 7(3):169-81. PubMed ID: 17318210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor.
    Crawford J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S78-86. PubMed ID: 19795580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer.
    Sève P; Reiman T; Dumontet C
    Lung Cancer; 2010 Feb; 67(2):136-43. PubMed ID: 19828208
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Integrating new targeted agents into the treatment of non-small-cell lung cancer.
    Thatcher N
    Lung Cancer; 2006 Dec; 54 Suppl 2():S25-31. PubMed ID: 17056150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
    Pennell NA; Lynch TJ
    Oncologist; 2009 Apr; 14(4):399-411. PubMed ID: 19357226
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Excision repair cross-complementation group 1 (ERCC1) in platinum-based treatment of non-small cell lung cancer with special emphasis on carboplatin: a review of current literature.
    Vilmar A; Sørensen JB
    Lung Cancer; 2009 May; 64(2):131-9. PubMed ID: 18804893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for overcoming acquired resistance to epidermal growth factor receptor: targeted therapies in lung cancer.
    Oxnard GR
    Arch Pathol Lab Med; 2012 Oct; 136(10):1205-9. PubMed ID: 23020725
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.